कंपनी का अवलोकन
Lexaria Bioscience Corp. operates primarily within the healthcare sector, specifically focusing on the biotechnology industry, where it develops and leverages proprietary drug delivery technologies. The company's core business involves offering a patented platform called DehydraTECH, which integrates active pharmaceutical ingredients with specific long-chain fatty acid-rich triglyceride oils and carrier compounds designed to enhance drug delivery efficacy. As of the latest available data, the firm maintains a market capitalization of $22.52M and employs a workforce of 7 individuals to execute its research and development initiatives. With an annual revenue of $522,000, the company operates on a micro-cap scale, indicating that it is an early-stage biotechnology entity with limited current commercialization traction relative to its market capitalization.
वित्तीय स्वास्थ्य
Lexaria Bioscience Corp. reported a total revenue of $522,000 over the trailing twelve months, yet it incurred a net income loss of $-10,793,149, revealing a significant structural gap where operating expenses vastly exceed generated sales. The company's EBITDA stands at $-10,444,801, further illustrating that the current cost structure involves substantial expenditures for research, development, or general corporate overhead that are not yet offset by product sales. Free cash flow for the period was $-4,779,293, which indicates that the company is burning through cash reserves to fund its operations and technology development rather than generating liquidity from its business activities. The gross margin is reported at 100.0%, suggesting that the cost of goods sold is negligible compared to revenue, likely due to the intellectual property-based nature of its product offerings where manufacturing costs are minimal or outsourced. However, the operating margin is severely negative at -2014.6%, and the profit margin is 0.0%, highlighting that administrative and research costs are consuming all operating income before reaching the bottom line. On the liability side, the company holds $4.42M in cash against $101,920 in total debt, resulting in a debt-to-equity ratio of 2.25, which suggests a balance sheet that is technically leveraged on paper but heavily reliant on equity financing rather than traditional bank borrowing. Despite the negative earnings, the current ratio of 3.68 indicates strong short-term liquidity, as the firm possesses more than three times the current assets required to meet its short-term obligations. Furthermore, the return on equity is -155.2% and the return on assets is -83.0%, metrics that reveal management has not yet generated positive returns on the capital invested in the business, reflecting the high-risk nature of early-stage biotechnology development.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is calculated at -2.32, implying that analysts or data providers project continued negative earnings in the immediate future. The price-to-book ratio stands at 4.09, indicating that the market values the company at a significant premium over its tangible book value, a common valuation characteristic for biotechnology firms where intangible assets like patents and proprietary platforms drive value rather than physical assets. Additionally, the price-to-sales ratio is 43.14, and the EV/EBITDA is -1.71, suggesting that investors are pricing the stock based on potential future drug approvals and platform utility rather than current profitability or cash flow generation. The stock price has fluctuated between a 52-week low of $0.46 and a 52-week high of $1.69, meaning the current trading price sits within this established range, reflecting the volatility typical of small-cap biotech stocks. The beta value is 0.48, which indicates that the stock's price volatility is less than the broader market, suggesting it may move less dramatically than the overall market index despite its small market cap.
Growth & Income
Lexaria Bioscience Corp. has neither reported revenue growth nor earnings growth year-over-year, as indicated by N/A figures for both metrics, reflecting the company's status as a pre-revenue or early-revenue entity where historical growth rates are not yet established. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically reinvested into the business, though currently, the company is consuming cash reserves to sustain operations. Consequently, the firm does not offer income generation for shareholders but instead relies entirely on capital appreciation driven by the successful commercialization of its DehydraTECH platform and future market penetration. The overall growth and income profile is characterized by a lack of historical expansion data and an absence of dividend payments, positioning the asset purely as a speculative investment dependent on future clinical milestones and regulatory approvals.